Approved indications: In the United States, Sirturo is approved as part of a combination regimen for adults and children (2 years and older and weighing at least 8 kg) with pulmonary tuberculosis caused by Mycobacterium tuberculosis that is resistant to at least rifampin and isoniazid; it is not approved for latent TB infection, drug‑sensitive TB, extra‑pulmonary TB, or infections due to non‑tuberculous mycobacteria.

Off‑label uses: Specialists may use bedaquiline off label in complex drug‑resistant TB (for example, broader multidrug‑ or extensively drug‑resistant TB patterns, extra‑pulmonary disease, or in certain shorter all‑oral regimens) or in situations not fully matching the U.S. label, but such use is guided by expert TB centers and international data and should be individualized.

Efficacy expectations: When combined with an effective background regimen, many patients show improvement in cough and energy over several weeks, and sputum cultures often become negative within about 2–3 months, with higher overall treatment success rates and fewer relapses compared with older multidrug‑resistant TB regimens that did not include bedaquiline.

Comparison to similar drugs: Compared with older injectable drugs used for resistant TB, Sirturo helps enable all‑oral regimens, is generally more effective at achieving culture conversion, and avoids injection‑related side effects, but it has important risks such as QT‑interval prolongation and liver toxicity that require careful monitoring.

Typical adult dosing: For most adults, Sirturo is taken by mouth with food as 400 mg once daily during Weeks 1 and 2, then 200 mg three times per week (with at least 24 hours between doses) from Weeks 3 to 24, always in combination with other TB medicines, and treatment may occasionally be extended beyond 24 weeks in selected older, heavier patients under specialist supervision.

Pediatric dosing: Children 2 years and older who weigh at least 8 kg receive weight‑based doses once daily for 2 weeks, then three times per week for 22 weeks, following the same 24‑week structure as adults; the exact milligram dose is calculated by the TB specialist based on the child’s weight band.

How to take the medicine: Sirturo must be taken with food to improve absorption; 100 mg tablets are swallowed whole with water, while 20 mg tablets can be swallowed whole, split at the score line, dispersed in water, mixed with soft food, or given through certain feeding tubes, according to the instructions provided by the clinician or pharmacist.

Special dosing instructions: Sirturo should never be used alone; it should always be part of a multidrug regimen with at least several other medicines active against the person’s TB strain, and doses are usually given under close supervision to support adherence and monitoring.

Missed‑dose guidance: If a dose is missed during the first 2 weeks, the missed dose should be skipped and the regular once‑daily schedule resumed without doubling up; from Week 3 onward, a missed dose should be taken as soon as remembered, then the usual three‑times‑weekly schedule continued, ensuring no more than the recommended total weekly dose and at least 24 hours between doses.

Overdose: If more Sirturo is taken than prescribed, the person should seek immediate medical care or contact a poison control center, and heart rhythm and liver function may need to be monitored closely.

Common side effects: The most frequent side effects include nausea, joint pain, headache, coughing up blood (from underlying lung disease), chest pain, decreased appetite, rash, and increases in liver enzymes; these usually appear in the first weeks to months of treatment and are often mild to moderate but should be reported if persistent or bothersome.

Serious or rare adverse effects: Sirturo can prolong the heart’s QT interval and, rarely, lead to dangerous heart rhythm problems, especially if combined with other QT‑prolonging drugs or in people with low potassium or magnesium; it can also cause serious liver injury with jaundice, dark urine, pale stools, or persistent abdominal pain, and an unexplained imbalance in deaths was seen in early clinical trials, so new or severe symptoms (fainting, palpitations, severe fatigue, yellow eyes/skin) need urgent medical attention.

Warnings and precautions: Use requires caution in people with known long‑QT syndrome, prior serious arrhythmias, significant heart disease, or those taking other QT‑prolonging medicines; in mild to moderate liver or kidney disease, no routine dose adjustment is needed but closer monitoring is recommended, while use in severe hepatic impairment or severe renal failure (including dialysis) should be cautious and specialist‑guided; safety and effectiveness are not established in children under 2 years or under 8 kg, and in pregnancy or breastfeeding Sirturo is used only if the potential benefit outweighs possible risk because human data are limited.

Overall safety profile: Compared with many older injectable drugs for multidrug‑resistant TB, Sirturo avoids hearing loss and kidney failure but carries distinct risks of QT prolongation and liver injury, so it is reserved for drug‑resistant TB where benefits clearly justify these monitored risks.

Monitoring and reporting: Patients typically need ECGs before starting and periodically during therapy, as well as regular blood tests for electrolytes and liver function; side effects should be reported to the prescribing clinician and can also be reported directly to the FDA’s MedWatch program or to the drug manufacturer, and patients should review the Medication Guide for any new safety updates.

Prescription and OTC drug interactions: Strong or moderate CYP3A4 inducers (such as rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, and St. John’s wort) can lower Sirturo levels and reduce effectiveness and are generally avoided, while strong or moderate CYP3A4 inhibitors (such as ketoconazole, itraconazole, clarithromycin, some HIV protease inhibitors, and certain calcium channel blockers) can raise Sirturo levels and increase side‑effect risks, requiring careful selection of TB and HIV regimens and close monitoring.

QT‑prolonging medicines: Combining Sirturo with other drugs that prolong the QT interval (for example, some fluoroquinolones, macrolide antibiotics, clofazimine, certain antipsychotics, methadone, or class I and III antiarrhythmics) can add to the risk of dangerous heart rhythm problems and should be avoided or used only with strong justification and ECG monitoring.

Alcohol, supplements, and foods: Regular alcohol use and other hepatotoxic substances (such as high‑dose acetaminophen or some azole antifungals) increase the chance of liver damage and should be minimized or avoided; herbal products that affect the liver or CYP3A4 (notably St. John’s wort) should not be used, and while there are no major food restrictions besides taking Sirturo with food, grapefruit and grapefruit juice may increase drug levels and are generally discouraged.

Conditions requiring extra caution: Extra care is needed in people with a history of long‑QT syndrome, heart failure, recent heart attack, significant electrolyte abnormalities, moderate to severe liver disease, severe kidney impairment or dialysis, HIV infection receiving interacting antiretrovirals, and in pregnant or breastfeeding individuals, all of whom require individualized risk‑benefit assessment and specialist oversight.

Monitoring needs: Before and during treatment, clinicians typically obtain ECGs (for example at baseline and during therapy), check blood potassium, magnesium, and calcium, perform regular liver function tests, review all medicines and supplements at each visit, and monitor TB response with clinical assessment and sputum testing to ensure the regimen remains effective and safe.

Q: What is Sirturo used for?
A: Sirturo is used, together with other TB medicines, to treat pulmonary tuberculosis caused by Mycobacterium tuberculosis that is resistant to at least rifampin and isoniazid in adults and in children 2 years and older who weigh at least 8 kg.

Q: How long will I need to take Sirturo?
A: Most people take Sirturo for 24 weeks (about 6 months) as part of a longer overall TB treatment plan that usually continues with other medicines beyond that period.

Q: How soon will I start to feel better on Sirturo?
A: Some symptoms, like cough and fatigue, may begin to improve within a few weeks, but TB bacteria often take several months to clear, so it is important to keep taking all prescribed medicines for the full course even if you feel better.

Q: Can I drink alcohol while taking Sirturo?
A: Alcohol can increase the risk of liver damage when combined with Sirturo and other TB drugs, so your care team will usually advise avoiding or strictly limiting alcohol during treatment.

Q: What should I do if I miss a dose?
A: If you miss a dose in the first 2 weeks, skip it and take your next dose at the usual time; from Week 3 onward, take the missed dose as soon as you remember, then continue your regular three‑times‑weekly schedule, and never take extra doses to make up for a missed one.

Q: Do I need special tests while taking Sirturo?
A: Yes, you will usually have ECGs to check your heart rhythm, blood tests to monitor your liver and electrolytes, and periodic sputum tests to see if the TB bacteria are clearing, so it is important to keep all scheduled appointments.

Storage: Store Sirturo tablets at room temperature (about 68°F to 77°F / 20°C to 25°C), in the original tightly closed bottle, protected from light and moisture; do not remove the desiccant packet from 20 mg bottles, and keep the medicine out of the reach of children.

Disposal: Use a medicine take‑back program if available; if none is accessible, mix unused tablets (not crushed) with an undesirable substance (such as used coffee grounds or cat litter), place the mixture in a sealed bag or container, and throw it in household trash, and never share Sirturo with others.